The urinary excretion of pyridinium cross-links was measured in 70 second morning urine samples from 49 patients following renal transplantation.
Introduction
index of the activity of bone resorption (e. g. due to prirr, "™, ^ , . mary hyperparathyroidism) (3). Type I collagen accounts for about 90% of the organic matrix of mineralized bone, the organic matrix is stabi-Bone alkaline phosphatase (EC 3.1.3.1) is localized in lized by the formation of pyridinium cross-links between the plasma membrane of osteoblastic cells and may be the terminal, non-helical part of a type I collagen mole-considered as a marker of osteoblastic activity and of cule and the helical region of another. The cross-links bone formation (4) .
found in type I collagen of bone are formed from two j n chronic renal failure secondary hyperparathyroidism hydroxylysine residues and one lysine residue (= de-ensues from diminished calcitriol production and imoxypyridinoline) or from three hydroxylysine residues paired excretion of inorganic phosphate. This leads to (= pyridinoline) (1) . When the collagen matrix is de-different forms of osteopathy including osteitis fibrosa, graded, both kinds of cross-links are released into the osteomalacia and suppressed bone remodeling, circulation and excreted in the urine. Deoxypyridinoline Following renal transplantation, the restoration of glois found almost exclusively in bone, whereas pyridino-merular filtration does not always completely normalize line is located in the collagen fibrils of bone as well the structure and function of bone tissue (e. g. hyperas cartilage (for review see 1. c. (2)). The excretion of parathyroidism may persist due to the increased mass of pyridinium cross-links in urine is considered to be an the parathyroid glands). Additionally, new skeletal de-rangements result from the action of the immunosuppressive agents that are used to maintain the allograft (for review see 1. c. (5)).
The present report describes the use of a competitive enzyme immunoassay for determination of the urinary excretion of pyridinium cross-links in the follow-up of patients receiving renal transplants. Excretion values for pyridinium cross-links were compared with bone alkaline phosphatase mass concentrations (as determined immunoradiometrically) as well as with intact parathyrm concentrations in plasma.
Parts of this work have been presented in a preliminary form (6).
Materials and Methods

Patients
We examined 90 venous blood specimens (serum as well as plasma; in the latter case the potassium salt of ethylenediammetetraacetic acid was used as anticoagulant) and 70 second morning urine samples from 49 patients (26 males, 23 females; age-range 25-66 years) who had undergone cadaveric renal transplantation. Samples were obtained between 8.00 and 10.00 a.m.
Cyclosporin A was given i. v. during the first 2 postoperative days at a daily dose of 1 mg/kg body weight, thereafter in daily oral doses of 5 mg/kg body weight. The dosage was adapted to achieve a concentration of cyclosporin A in whole blood between 120 and 160 μg/l (for determination of cyclosporin A see below). Azathioprine was given at a daily oral dose of 2 mg/kg body weight. Methylprednisolone was given during the first 2 postoperative days at a daily dose of 250 mg i. v., during the next 4 days at a daily oral dose of 100 mg, followed thereafter by a daily oral dose of 1 mg/ kg body weight, gradually decreasing to 0.1 mg/kg body weight 2 months after transplantation. Tables 1 and 2 give further information on the sampling times of serum, plasma and urine.
shows 100% cross-reactivity with deoxypyridinolme. A calibration curve was constructed by employing a 4-parameter curve fitting equation. Between-assay imprecision was < 10% Urinary excretion of pyridinium cross-links is given as pyndmolme equivalents in μηιοΐ/mol creatinine. The creatinine concentration in serum and urine was determined with the fully mechanized analyser Hitachi/BM 704 (Boehringer Mannheim GmbH, Mannheim, Germany), employing a kinetic modification of the Jaffe procedure (7).
Tab. 
Determination of cyclosporin A in whole blood
Cyclosporin A was determined in the supernate of deproteinized whole blood (anticoagulant: potassium salt of ethylenediaminetetraacetic acid), employing the analyser TDx® (Abbott GmbH, Wiesbaden, Germany) and a monoclonal antibody against cyclosporin A.
Statistical methods
The statistical methods employed include the U-test according to Wilcoxon, Mann & Whitney (two-tailed) for unpaired samples, linear regression equations, as well as linear correlation coefficients (9) .
Results
Cross-sectional study of biochemical quantities before and after renal transplantation Follow-up of the excretion of pyridinium cross-links and the concentration of bone alkaline phosphatase after renal transplantation
The plasma concentration of bone alkaline phosphatase and the urinary excretion of pyridinium cross-links were monitored in 12 patients who showed a bone alkaline phosphatase concentration within (10 cases) or below the reference interval (2 cases).
There was a decrease of bone alkaline phosphatase 1 week after renal transplantation (p < 0.01) compared with the corresponding concentrations before transplantation. Bone alkaline phosphatase concentrations increased again 1 month following transplantation (p < 0.05). Three months after transplantation, bone alkaline phosphatase mass concentrations were higher than before transplantation (p < 0.05). There was a rise in the urinary excretion of pyridinium cross-links 1 and 3 months after transplantation, compared with the corresponding values 1 week following transplantation (p < O. 5). Excretion levels of cross-links and mass concentrations of bone alkaline phosphatase were correlated at all times following transplantation (p < 0.001) (tab. 5 and fig. 4 ).
Discussion
Persistence of high intact parathyrin concentrations r M · ι , . . / , following renal transplantation is due to a hypersecretion of this hormone by hyperplastic parathyroid glands (10) .
A follow-up revealed a rise of bone alkaline phosphatase concentrations 3 months after renal transplantation. In view of the lack of correlation between intact parathyrin and bone alkaline phosphatase concentrations, it seems unlikely that parathyrin action on bone tissue is responsible for this increase.
Several groups have observed an increase of bone alkaline phosphatase following renal transplantation (II, 12) which is most probably due to an activation of osteoblasts by cyclosporin A (13) The urinary excretion of pyridinium cross-links was increased 1 and 3 months after renal transplantation. This may be due either to high bone remodelling induced by cyclosporin A (15) or to an enhancement of bone resorption caused by glucocorticoids (16) .
Glucocorticoids cause bone loss by diminishing the conversion of precursor cells to functioning osteoblasts and by decreasing the synthesis of collagen (5) . A decrease of bone alkaline phosphatase values within the first week following renal transplantation can be explained by the high doses of corticosteroids given in this period (17) .
There was a correlation between the serum mass concentrations of bone alkaline phosphatase and the urinary concentrations of pyridinium cross-links following renal transplantation. This is in concordance with findings in patients with primary hyperparathyroidism (3) or bone metastases (18) , in which osteobla'stic and osteoclastic activity are usually coupled.
For the interpretation of bone alkaline phosphatase values (as determined immunoradiometrically) it has to be taken into account that the antibodies employed in the test show 16% cross reactivity with liver alkaline phosphatase (19, 20) . In the sera examined in the present study interference by liver alkaline phosphatase can be excluded since all sera with increased bone alkaline phosphatase mass concentrations showed Ζ,-γ-glutamyl transferase activity concentrations within the reference range.
It is worth mentioning that only 2 (12%) out of 17 urines with excretion values of pyridinium cross-links above the upper reference limit were characterized by increased bone alkaline phosphatase values. In patients following renal transplantation simultaneous assessment of bone formation and bone resorption (determined frofrr bone alkaline phosphatase serum concentrations and the excretion of pyridinium cross-links) may therefore enhance the diagnostic sensitivity for detecting effects on bone metabolism.
